Olaptesed pegol - TME Pharma
Alternative Names: Anti-CXCL12/SDF-1 Spiegelmer®; NOX-A12Latest Information Update: 29 Jun 2023
At a glance
- Originator NOXXON Pharma AG
- Developer TME Pharma
- Class Antineoplastics; Eye disorder therapies; Oligonucleotides; Polyethylene glycols; Small molecules
- Mechanism of Action Chemokine CXCL12 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- Phase II Chronic lymphocytic leukaemia; Multiple myeloma
- Phase I/II Colorectal cancer; Glioblastoma; Pancreatic cancer
- Discontinued Diabetic retinopathy
Most Recent Events
- 28 Jun 2023 Updated efficacy data from the phase I/II GLORIA trial in Glioblastoma released by TME Pharma
- 15 Jun 2023 US FDA approves the phase II OPTIMUS trial protocol for Olaptesed pegol in Pancreatic cancer (Combination therapy, Second-line therapy or greater) in USA
- 15 Jun 2023 TME Pharma plans the phase II OPTIMUS trial for Pancreatic cancer (Combination therapy, Second-line therapy or greater) in France, Spain and USA (NCT04901741) (EudraCT2021-001963-25)